Basic and clinical insights of Mu (μ)-opioid receptor in cancer
Gene & Protein in Disease · 29.03.2023 · 2 (2) · 282
DOI: 10.36922/gpd.282 ↗Kurz gefasst
Fachartikel in der Zeitschrift Gene & Protein in Disease, online erschienen am 29.03.2023. Verfasst von Ruidong Ding und 8 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Cancer is a public health problem that is extremely harmful to people’s health. Most cancer patients experience severe pain in the advanced stage, which will seriously affect their prognosis. At present, opioids, such as morphine, have been used as the drug of choice for treating moderate to severe cancer-related pain. Mu (μ)-opioid receptor (MOR) is expressed in many different cancer cells. In this article, we present the relationship between MOR and tumor pathophysiology; summarize the molecular mechanism and effect of MOR on tumor proliferation and progression, tumor angiogenesis, tumor immunity, and cancer therapy; and propose the future research direction of MOR for cancer treatment. MOR could be as a promising prognostic biomarker and immune checkpoint in cancer therapy.
Zitieren
APA
Ding, R., Zhao, Y., Li, J., Zhao, S., Su, D., Zhang, Y., Wang, J., Lv, S., & Ji, X. (2023). Basic and clinical insights of Mu (μ)-opioid receptor in cancer. Gene & Protein in Disease, 2(2), 282. https://doi.org/10.36922/gpd.282
Vancouver
Ding R, Zhao Y, Li J, Zhao S, Su D, Zhang Y, et al. Basic and clinical insights of Mu (μ)-opioid receptor in cancer. Gene & Protein in Disease. 2023;2(2):282. doi:10.36922/gpd.282
BibTeX
@article{Ding2023,
author = {Ding, Ruidong and Zhao, Yiming and Li, Jia and Zhao, Siyuan and Su, Dingyuan and Zhang, Yue and Wang, Jia-Yi and Lv, Shuangyu and Ji, Xinying},
title = {Basic and clinical insights of Mu (μ)-opioid receptor in cancer},
journal = {Gene & Protein in Disease},
year = {2023},
volume = {2},
number = {2},
pages = {282},
doi = {10.36922/gpd.282}
}
EUVIMED